Full Press Release Details
Sensus Healthcare Buys Back Shares
BOCA RATON, Fla. (February 11, 2025) -
Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive, minimally-invasive
and cost-effective treatments for oncological and non-oncological skin conditions, announces that the company has resumed purchasing shares
of its common stock in open-market transactions under a $3.0 million share repurchase program approved by its Board of Directors and announced
"We are implementing this program now as
we view the repurchase of our common stock as a compelling opportunity at current prices," said Joe Sardano, Chairman and CEO of
Sensus Healthcare. "We remain confident in our growth prospects and believe that returning capital to shareholders while maintaining
the flexibility to invest in our strategic initiatives best positions us to enhance value for all stakeholders. We completed a similar
$3 million repurchase program in 2022."
Today's announcement marks the resumption
of purchases under a Board-approved program that was announced in August 2023, providing for the purchase up to $3.0 million of the company's
common stock from time to time. Prior to the resumption of the program, 9,427 shares had been previously repurchased under the program.
The timing and amount of share repurchases under this program are determined by Sensus Healthcare's management at its discretion
based upon its ongoing assessments of the capital needs of the business, the market price of Sensus' common stock and general market
conditions. Share repurchases under this program may be made through a variety of methods, including open-market purchases, block trades,
exchange transactions or any combination thereof. The program does not obligate Sensus to acquire any particular amount of its common
stock, and the share repurchase program may be suspended or discontinued at any time at the company's discretion.
About Sensus Healthcare
Healthcare, Inc. is a global pioneer in the development and delivery of non-invasive treatments for skin cancer and keloids. Leveraging
its cutting-edge superficial radiotherapy (SRT and IG-SRT) technology, the company provides healthcare providers with a highly effective,
patient-centric treatment platform. With a dedication to driving innovation in radiation oncology, Sensus Healthcare offers solutions
that are safe, precise, and adaptable to a variety of clinical settings. For more information, please visit www.sensushealthcare.com.
Forward-Looking Statements
This press release includes statements that are,
or may be deemed, ''forward-looking statements.'' In some cases, these statements can be identified by the use of forward-looking terminology
such as "believes," "estimates," "anticipates," "expects," "plans," "intends,"
"may," "could," "might," "will," "should," "approximately," "potential"
or negative or other variations of those terms or comparable terminology, although not all forward-looking statements contain these words.
Forward-looking statements involve risks and uncertainties
because they relate to events, developments, and circumstances relating to Sensus, our industry, and/or general economic or other conditions
that may or may not occur in the future or may occur on longer or shorter timelines or to a greater or lesser degree than anticipated.
In addition, even if future events, developments, and circumstances are consistent with the forward-looking statements contained in this
press release, they may not be predictive of results or developments in future periods. Although we believe that we have a reasonable
basis for each forward-looking statement contained in this press release, forward-looking statements are not guarantees of future performance,
and our actual results of operations, financial condition and liquidity, and the development of the industry in which we operate may differ
materially from the forward-looking statements contained in this press release, as a result of the following factors, among others: the
possibility that inflationary pressures continue to impact our sales; the level and availability of government and/or third party payor
reimbursement for clinical procedures using our products, and the willingness of healthcare providers to purchase our products if the
level of reimbursement declines; concentration of our customers in the U.S. and China, including the concentration of sales to one particular
customer in the U.S.; the development by others of new products, treatments, or technologies that render our technology partially or wholly
obsolete; the regulatory requirements applicable to us and our competitors; our ability to efficiently manage our manufacturing processes
and costs; the risks arising from doing business in China and other foreign countries; legislation, regulation, or other governmental
action that affects our products, taxes, international trade regulation, or other aspects of our business; the performance of the Company's
information technology systems and its ability to maintain data security; our ability to obtain and maintain the intellectual property
needed to adequately protect our products, and our ability to avoid infringing or otherwise violating the intellectual property rights
of third parties; and other risks described from time to time in our filings with the Securities and Exchange Commission, including our
Annual Reports on Form 10-K and Quarterly Reports on Form 10-Q.
Any forward-looking statements that we make in
this press release speak only as of the date of such statement, and we undertake no obligation to update such statements to reflect events
or circumstances after the date of this press release, except as may be required by applicable law. You should read carefully our "Introductory
Note Regarding Forward-Looking Information" and the factors described in the "Risk Factors" section of our periodic reports
filed with the Securities and Exchange Commission to better understand the risks and uncertainties inherent in our business.
Alliance Advisors IR